Pharma Pulse 5/9/2025: Teva Plots Thousands of Job Cuts as Restructuring Drive Enters 'Acceleration' Phase, Takeda to Invest $30B Into US Operations
Teva plots thousands of job cuts as restructuring drive enters 'acceleration' phase
Teva is set to cut around 2,400 jobs, about 8% of its workforce, as part of its "Acceleration Phase" in the ongoing restructuring plan aimed at saving $700 million by 2027, streamlining operations, and strengthening its position in generics and innovative medicines.
Takeda to Invest $30B into US Operations
Takeda has announced plans to invest $30 billion into its US operations over the next five years, highlighting the US as a leading market for biopharmaceutical innovation amid potential tariff threats.
Time Horizon: An Early Career Perspective
In a reflection on career planning, Troy Trygstad emphasizes the importance of considering long-term time horizons, particularly in pharmacy, where changing business models, emerging technologies like AI, and evolving clinical services will shape the future of the profession.
Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case
Hikma Pharmaceuticals has agreed to pay $50 million to settle a class action lawsuit accusing the company of delaying a generic version of Jazz Pharmaceuticals' narcolepsy drug, Xyrem, thereby causing higher prices for health plans, with a separate $145 million settlement from Jazz also in place.
US judge sides with FDA's removal of Lilly's weight loss drug from shortage list
A US federal judge has upheld the FDA's decision to remove Eli Lilly's weight loss drugs Zepbound and Mounjaro from the shortage list, halting compounding pharmacies from producing generic versions of the drugs.
